Form 4: Hologic Director Acquires 3,190 Restricted Stock Units

Hologic Inc. Director Charles J. Dockendorff acquired 3,190 restricted stock units, aligning his interests with shareholders.

Summary

• Hologic Inc. Director Charles J. Dockendorff acquired 3,190 restricted stock units (RSUs) on February 26, 2026.
• These RSUs are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders.
• Upon vesting, the restricted stock units will be settled in shares of common stock on a one-for-one basis.
• Following this transaction, Mr. Dockendorff directly beneficially owns 6,626 shares of common stock and indirectly owns 15,370 shares through a revocable trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued insider alignment with shareholder interests through equity compensation, which is a standard practice.

Positives

• Director Charles J. Dockendorff increased his beneficial ownership in Hologic Inc. through the acquisition of 3,190 restricted stock units.
• The grant of restricted stock units aligns the director's long-term interests with those of the company's shareholders, as the value is tied to future stock performance.

Negatives

• No negative information is present in this Form 4 filing.

Risks

• The value of the restricted stock units is subject to the future performance of Hologic Inc.'s common stock, meaning the ultimate value realized by the director could be lower than the grant date value if the stock price declines.
• The vesting of the restricted stock units is contingent upon Mr. Dockendorff's continued service until the 2027 Annual Meeting of Stockholders.

Future Outlook

The restricted stock units granted to Director Charles J. Dockendorff are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders, indicating a future milestone for the conversion of these units into common stock.

Industry Context

StockSavvy.ai notes that grants of restricted stock units to directors are a common form of executive and director compensation across various industries, including healthcare technology, to incentivize long-term performance and align leadership interests with shareholder value. This practice is standard for companies like Hologic Inc. in the medical device and diagnostics sector.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard compensation practice in publicly traded companies, particularly within the healthcare technology sector.
• Companies such as Intuitive Surgical (ISRG) and Stryker Corporation (SYK) also utilize RSU grants as part of their director compensation packages to foster long-term commitment and align interests.
• The specific number of units granted (3,190) would typically be benchmarked against peer companies' director compensation for similar roles and responsibilities, considering Hologic's market capitalization and performance.

Corporate Governance

Related Party Transactions

• The acquisition of restricted stock units by Director Charles J. Dockendorff from Hologic Inc. constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of shareholders, potentially fostering better long-term decision-making.

Next Steps

• The 3,190 restricted stock units are expected to vest on the date of the 2027 Annual Meeting of Stockholders.

Key Dates

Recommendation

This Form 4 filing details a routine grant of restricted stock units to a director, which is a standard compensation practice. While it indicates insider alignment, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Hologic Inc., HOLX, Form 4, Restricted Stock Units, RSU, Insider Trading, Director Compensation, Beneficial Ownership, Stock Grant, Corporate Governance